trending Market Intelligence /marketintelligence/en/news-insights/trending/0_fob5z4o6imbmf00asqpq2 content esgSubNav
In This List

Cynata stem cell therapy gets US orphan drug status

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Cynata stem cell therapy gets US orphan drug status

The U.S. Food and Drug Administration granted orphan drug status to Cynata Therapeutics Ltd.'s stem cell therapy CYP-001.

The drug is meant to treat the acute graft versus host disease, which occurs after transplant procedures when immune cells from transplanted tissue attack the recipient. The disease has a high mortality rate.

The orphan drug status will help expedite development of CYP-001 and entitles Cynata to seven years of exclusive market rights and tax credits once the treatment is commercialized.

CYP-001 is being studied in an early stage trial.